ClinicalTrials.gg
Not yet recruitingNCT06502197Updated Jul 16, 2024

Comparative Analysis of Silastic Stenting in Sinus Surgery

An interventional study of Silastic Stenting in Chronic Rhinosinusitis (Diagnosis), sponsored by University of British Columbia. Not yet recruiting. Open to participants aged 19 Years to 89 Years. Per ClinicalTrials.gov, last updated 2024-07-16.

Primary conditionnone(registry's first term: Disease)No conditionIs this wrong?Disease describes something many studies share rather than a condition a study is about. The study names no condition we can place it under, so it is not compared with other studies by condition.

Sponsored by University of British Columbia · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 2 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Non-randomized
Ages
19 Years to 89 Years
Sex
All
01

Study summary

Silastic stenting is a measure taken to support tissue healing following sinus surgery. Silastic stents are inserted into the sinus cavities and provide structural support while facilitating healing in the critical period of recovery following surgery. There is controversy over the optimal duration for which silastic stents should be left in place. Having them in place for shorter periods may reduce the likelihood of stent-related reactions, while leaving them for longer periods could promote more tissue healing. The aim of this study is to compare the impact of stent duration on clinical outcomes of patients following sinus surgery.

Read the detailed description

Patients will be recruited consecutively from the PI's frontal sinus surgery list. The research assistant will approach the patient to obtain informed consent before the day of the operation. A written patient information leaflet explaining the study will be provided.

Eligible patients will be categorized into two groups:

  • Group A: Short-term stent retention (4 weeks)
  • Group B: Long-term stent retention (12 weeks) We aim for a sequence of 50 "4 week-stent" and 50 "12 week-stent". The patients will be told whether they are receiving the stent for 4 or 12 weeks at the day of surgery.

Standard of care:

  1. Preoperative visit, assessment including nasal endoscopy and completion of SNOT-22 baseline questionnaire.
  2. Surgery with frontal sinus drill out (Draf IIa, IIb, \&III) are done as a standard of care in these centers. Dressing of the raw drilled out surface area of the beak with silastic stents is the standard of care for all drill outs.
  3. Post-operative follow-ups at 4 weeks and 12 weeks', with 4 weeks vs 12 weeks of stent removal time scale.

Study will require:

  1. Categorization of patients into two groups: one group who will have a silastic stent for 4 weeks, and the other group will have stent in place for 12 weeks.
  2. Saving a copy of the endoscopic image intra-operative and at 6 months and one-year post-op. To compare the size of a frontal drainage pathway, measuring anterior-posterior \& medial-lateral diameters.

Study Process:

At the first pre-operative appointment for drill out, the procedure is discussed. At this point, the study will be introduced by the principal and sub investigators and explained in detail by the research coordinator who would also obtain informed consent. If the patient consents to the study, a SNOT22 (sino-nasal outcome measure 22) pre-operative questionnaire will be completed; thereafter, they will be categorized to one of the two groups.

At time of surgery, frontal stent placement is placed to minimize contracture and to aid with re-mucolisation of the raw surface area due to the drill out, allowing for creation of optimal frontal sinus opening. Therefore, after the maximal desired sinus drill out has been achieved, and the surgeon feels that the surgery proceeded routinely, with no circumstances that would indicate the use of silastic stents for other reasons (such as injury to posterior plate mucosa or 360 mucosal disruption), an envelope that indicates which arm of the study the patient will be opened and the choice for placement of the stent for what time interval would be revealed to the surgeon. In the event of a non-routine surgery, the surgeon will complete the surgery as required by the circumstance, and the patient will be withdrawn from the study. The information about withdrawal will be communicated to the participant immediately post-operative, and during their first routine follow-up appointment.

For all participants that provide informed consent, a routine follow-up endoscopic assessment will be performed as per standard of care at 4 weeks, 12 weeks, 6 months and 1 year. During these examinations an endonasal photograph will be taken for measurement and analyzing. Photographs will be evaluated by two independent surgeons to reduce bias.

At the second and final 1-year postoperative follow-ups, the patients will be asked to complete two brief questionnaires of the patient-reported experience related to healing. Questionnaires on symptoms: one is the validated SNOT22 scoring system and the other was adopted from SNOT22; both address health related issues concerning the quality of life as pertain to sinus disease1. The second questionnaire includes the following items that relate to the study aims:

A) During the post-operative process:

  • Nasal obstruction (none-mild-moderate-severe)
  • Crusting (none-mild-moderate-severe)
  • Cacosmia (none-mild-moderate-severe)
  • Halitosis (none-mild-moderate-severe)
  • Nasal discomfort (none-mild-moderate-severe)
  • Acute sinus infection (when, duration, antibiotic requirement).

B) Experience of the post-operative appointment:

  • Pain association with debridement and/or stent removal [graded on a visual analogue scale where 0 is no pain (none) and 10 is the worst (severe) pain ever experienced]
  • Did the patients adhere to taken analgesia (Tylenol / Paracetamol) 30 mins pre-procedure.
02

Conditions studied

  • Chronic Rhinosinusitis (Diagnosis)

Browse trials for

Keywords

  • Chronic Rhinosinusitis, Endoscopic Sinus Surgery, Silastic Stenting
03

In context

Lead sponsor

University of British Columbia is the lead sponsor of 1,339 studies on the registry; 259 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 89 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed with chronic rhinosinusitis requiring Frontal drill-out.

Exclusion criteria

Exclusion Criteria:

  • Patients unwilling or unable to comply with the study protocol.
  • Previous Radiotherapy to operated area.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Short-term (4 weeks) Silastic Stenting

    Procedure: Silastic Stenting

  • Experimental
    Long-term (12 weeks) Silastic Stenting

    Procedure: Silastic Stenting

Interventions

  • ProcedureSilastic Stenting

    Drill-out frontal sinus procedures, are a well-established surgical intervention in the management of CRS, involves extensive sinus surgery with the creation of a large, surgically exposed area of raw bone. This raw bone, left exposed postoperatively, poses a unique challenge in the context of mucosal healing. Silastic stents, inserted into the sinus cavities, offer a promising solution by providing structural support and facilitating mucosal re-mucolisation in this critical period of postoperative recovery.

06

What researchers measure

Primary outcomes

  1. Long-Term Patency

    Patency is to be assessed by using the validated scoring system from Lund VJ, Kennedy DW. Quantification for staging sinusitis. In: Kennedy DW, editor. International Conference on Sinus Disease: Terminology, Staging, Therapy. Ann Otol Rhinol Laryngol 1995; 104(Suppl 167):17-21.

    Time frame: 6 and 18 months

  2. Incidence of acute sinus infection

    The occurrence and frequency of acute sinusitis in both cohorts, requiring rescue course of oral antibiotics.

    Time frame: 2 and 4 weeks

Secondary outcomes

  1. Tolerability Assessment

    Instrument: Likert Scale

    Time frame: At the respective stent extraction time

  2. Symptom Relief Assessment

    Instrument: Sinonasal Outcome Test-22 (SNOT-22)

    Time frame: 6 and 18 months post-op

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2024; primary completion for Sep 2025, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2024
First posted
Jul 16, 2024
StartEst.
Sep 2, 2024
Primary completionEst.
Sep 2, 2025
CompletionEst.
Mar 2, 2026
Last update
Jul 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06502197
Collaborators
Addenbrooke's Hospital, Cambridge University, NHS Greater Glasgow and Clyde
Responsible party
Arif Janjua (Clinical Professor, University of British Columbia) — Principal investigator
First posted
Jul 16, 2024
Start date
Sep 2, 2024 (estimated)
Primary completion
Sep 2, 2025 (estimated)
Completion
Mar 2, 2026 (estimated)
Last update
Jul 16, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion